Bill Text: NY S04587 | 2025-2026 | General Assembly | Introduced

New York Senate Bill 4587

Introduced

Bill Title: Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2025-02-07 - REFERRED TO RULES [S04587 Detail]

Download: New_York-2025-S04587-Introduced.html


                STATE OF NEW YORK
        ________________________________________________________________________

                                          4587

                               2025-2026 Regular Sessions

                    IN SENATE

                                    February 7, 2025
                                       ___________

        Introduced  by  Sen.  MAYER  -- read twice and ordered printed, and when
          printed to be committed to the Committee on Rules

        AN ACT to amend the education law and the public health law, in relation
          to prescription labels for mifepristone and misoprostol

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:

     1    Section  1.  Paragraph  b-1  of  subdivision  1 of section 6807 of the
     2  education law, as added by a chapter of the laws of  2025  amending  the
     3  education law relating to the labeling of mifepristone, misoprostol, and
     4  their  generic alternatives, as proposed in legislative bills numbers S.
     5  36-A and A. 2145-A, is amended to read as follows:
     6    b-1. Notwithstanding paragraph b of  this  section,  the  prescription
     7  label  for  mifepristone[,]  or misoprostol[, and their generic alterna-
     8  tives] may include the name or address of  the  dispensing  health  care
     9  practice instead of the name of the dispenser.
    10    § 2. Subdivision 1-a of section 6810 of the education law, as added by
    11  a chapter of the laws of 2025 amending the education law relating to the
    12  labeling  of  mifepristone, misoprostol, and their generic alternatives,
    13  as proposed in legislative bills numbers  S.  36-A  and  A.  2145-A,  is
    14  amended to read as follows:
    15    1-a.   Notwithstanding   subdivision  one  of  this  section,  at  the
    16  prescriber's request, the  prescription  label  for  mifepristone[,]  or
    17  misoprostol[, and their generic alternatives may] shall include the name
    18  or  address  of the prescribing health care practice instead of the name
    19  of the prescriber.
    20    § 3. The public health law is amended by adding a new section 280-d to
    21  read as follows:
    22    § 280-d. Patient notification of prescription label change.  A  health
    23  care prescriber shall inform the patient if such prescriber has included
    24  or  has  requested  to  include  the  name or address of the prescribing

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD09082-01-5

        S. 4587                             2

     1  health care practice instead of the  name  of  such  prescriber  on  the
     2  prescription label when prescribing mifepristone or misoprostol.
     3    §  4.  This  act  shall  take  effect on the same date and in the same
     4  manner as a chapter of the laws  of  2025  amending  the  education  law
     5  relating to the labeling of mifepristone, misoprostol, and their generic
     6  alternatives,  as  proposed  in legislative bills numbers S. 36-A and A.
     7  2145-A, takes effect.